Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roivant Sciences Ltd.

10.15
+0.13001.30%
Post-market: 10.150.00000.00%16:25 EDT
Volume:2.62M
Turnover:26.61M
Market Cap:7.24B
PE:-65.20
High:10.22
Open:10.05
Low:10.01
Close:10.02
Loading ...

Company Profile

Company Name:
Roivant Sciences Ltd.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
908
Office Location:
50 Broadway,7th Floor,London,Greater London,United Kingdom
Zip Code:
SW1H 0DB
Fax:
- -
Introduction:
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Directors

Name
Position
Ilan Oren
Director and Chairman
Matthew Gline
Director and Chief Executive Officer
Daniel Gold
Director
Hiroshi Nomura
Director
James C. Momtazee
Director
Keith Manchester
Director
Meghan FitzGerald
Director
Melissa Epperly
Director

Shareholders

Name
Position
Matthew Gline
Director and Chief Executive Officer
Eric Venker
President and Chief Operating Officer
Richard Pulik
Chief Financial Officer
Mayukh Sukhatme
President and Chief Investment Officer
Rakhi Kumar
Chief Accounting Officer